Sökning: WFRF:(Reith Christina) > Effects of Lowering...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 03256naa a2200457 4500 | |
001 | oai:DiVA.org:uu-231243 | |
003 | SwePub | |
008 | 140905s2014 | |||||||||||000 ||eng| | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-2312432 URI |
024 | 7 | a https://doi.org/10.1681/ASN.20130909652 DOI |
040 | a (SwePub)uu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Haynes, Richard4 aut |
245 | 1 0 | a Effects of Lowering LDL Cholesterol on Progression of Kidney Disease |
264 | 1 | c 2014 |
338 | a print2 rdacarrier | |
520 | a Lowering LDL cholesterol reduces the risk of developing atherosclerotic events in CKD, but the effects of such treatment on progression of kidney disease remain uncertain. Here, 6245 participants with CKD (not on dialysis) were randomly assigned to simvastatin (20 mg) plus ezetimibe (10 mg) daily or matching placebo. The main prespecified renal outcome was ESRD (defined as the initiation of maintenance dialysis or kidney transplantation). During 4.8 years of follow-up, allocation to simvastatin plus ezetimibe resulted in an average LDL cholesterol difference (SEM) of 0.96 (0.02) mmol/L compared with placebo. There was a nonsignificant 3% reduction in the incidence of ESRD (1057 [33.9%] cases with simvastatin plus ezetimibe versus 1084 [34.6%] cases with placebo; rate ratio, 0.97; 95% confidence interval [95% CI], 0.89 to 1.05; P=0.41). Similarly, allocation to simvastatin plus ezetimibe had no significant effect on the prespecified tertiary outcomes of ESRD or death (1477 [47.4%] events with treatment versus 1513 [48.3%] events with placebo; rate ratio, 0.97; 95% CI, 0.90 to 1.04; P=0.34) or ESRD or doubling of baseline creatinine (1189 [38.2%] events with treatment versus 1257 [40.2%] events with placebo; rate ratio, 0.93; 95% CI, 0.86 to 1.01; P=0.09). Exploratory analyses also showed no significant effect on the rate of change in eGFR. Lowering LDL cholesterol by 1 mmol/L did not slow kidney disease progression within 5 years in a wide range of patients with CKD. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Urologi och njurmedicin0 (SwePub)302142 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Urology and Nephrology0 (SwePub)302142 hsv//eng |
700 | 1 | a Lewis, David4 aut |
700 | 1 | a Emberson, Jonathan4 aut |
700 | 1 | a Reith, Christina4 aut |
700 | 1 | a Agodoa, Lawrence4 aut |
700 | 1 | a Cass, Alan4 aut |
700 | 1 | a Craig, Jonathan C.4 aut |
700 | 1 | a de Zeeuw, Dick4 aut |
700 | 1 | a Feldt-Rasmussen, Bo4 aut |
700 | 1 | a Fellström, Bengtu Uppsala universitet,Njurmedicin4 aut0 (Swepub:uu)bengfell |
700 | 1 | a Levin, Adeera4 aut |
700 | 1 | a Wheeler, David C.4 aut |
700 | 1 | a Walker, Rob4 aut |
700 | 1 | a Herrington, William G.4 aut |
700 | 1 | a Baigent, Colin4 aut |
700 | 1 | a Landray, Martin J.4 aut |
710 | 2 | a Uppsala universitetb Njurmedicin4 org |
773 | 0 | t Journal of the American Society of Nephrologyg 25:8, s. 1825-1833q 25:8<1825-1833x 1046-6673x 1533-3450 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-231243 |
856 | 4 8 | u https://doi.org/10.1681/ASN.2013090965 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.